These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 1703239)

  • 21. [The clinical efficacy and safety of naftopidil 75 mg on benign prostatic hyperplasia patients with moderate or severe urinary disturbance].
    Tsujihata M; Yoshimura K; Kojima Y; Oda M; Miyake O; Uchida K; Okuyama A
    Hinyokika Kiyo; 2009 Apr; 55(4):181-6. PubMed ID: 19462821
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
    Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
    BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
    Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostatic hyperplasia.
    Weber JP; Oesterling JE; Peters CA; Partin AW; Chan DW; Walsh PC
    J Urol; 1989 Apr; 141(4):987-92. PubMed ID: 2467015
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Experimental approaches to treatment of prostatic adenoma with the luliberin analog surfagon].
    Smirnova IO; Balueva IM; Kiselev VI; Pavlova OM; Titov MI; Burenin IS
    Probl Endokrinol (Mosk); 1992; 38(1):52-4. PubMed ID: 1284993
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.
    McConnell JD; Bruskewitz R; Walsh P; Andriole G; Lieber M; Holtgrewe HL; Albertsen P; Roehrborn CG; Nickel JC; Wang DZ; Taylor AM; Waldstreicher J
    N Engl J Med; 1998 Feb; 338(9):557-63. PubMed ID: 9475762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist.
    Labrie F; Dupont A; Belanger A; Lachance R
    J Urol; 1987 Oct; 138(4):804-6. PubMed ID: 3309363
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Androgen deprivation in benign prostatic hypertrophy].
    Tenaglia R; Nicolai M; Di Federico G; Iantorno R; Zezza A; Lombardi G
    J Urol (Paris); 1993; 99(6):296-8. PubMed ID: 7516371
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Testicular histology after prolonged treatment with a gonadotropin-releasing hormone analogue.
    Smith JA; Urry RL
    J Urol; 1985 Apr; 133(4):612-4. PubMed ID: 3920405
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists.
    Tolis G; Ackman D; Stellos A; Mehta A; Labrie F; Fazekas AT; Comaru-Schally AM; Schally AV
    Proc Natl Acad Sci U S A; 1982 Mar; 79(5):1658-62. PubMed ID: 6461861
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group.
    Berges RR; Windeler J; Trampisch HJ; Senge T
    Lancet; 1995 Jun; 345(8964):1529-32. PubMed ID: 7540705
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group.
    Jardin A; Bensadoun H; Delauche-Cavallier MC; Attali P
    Lancet; 1991 Jun; 337(8755):1457-61. PubMed ID: 1710750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment of advanced prostatic cancer with a gonadorelin agonist, dTrp6 LHRH. 41 cases].
    Steg A; Chiche R; Boccon-Gibod L; Debré B
    Presse Med; 1985 Nov; 14(40):2045-8. PubMed ID: 2934695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intraprostatic botulinum toxin type a injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement. Effect on prostate volume and micturition resumption.
    Silva J; Silva C; Saraiva L; Silva A; Pinto R; Dinis P; Cruz F
    Eur Urol; 2008 Jan; 53(1):153-9. PubMed ID: 17825981
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Quality of life of patients with prostate cancer under androgen deprivation with GnRH analogues: Results of the noninterventional study TRIPTOSIX].
    Eisenhardt A; Schneider T; Scheithe K; Colling C; Heidenreich A;
    Urologe A; 2016 Feb; 55(2):176-83. PubMed ID: 26518305
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanisms of synergism between antagonists of growth hormone-releasing hormone and antagonists of luteinizing hormone-releasing hormone in shrinking experimental benign prostatic hyperplasia.
    Rick FG; Schally AV; Block NL; Abi-Chaker A; Krishan A; Szalontay L
    Prostate; 2013 Jun; 73(8):873-83. PubMed ID: 23280565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Use of LHRH agonists in the treatment of advanced cancer of the prostate].
    Fretin J
    Arch Esp Urol; 1990; 43(6):647-9. PubMed ID: 2151155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group.
    Gormley GJ; Stoner E; Bruskewitz RC; Imperato-McGinley J; Walsh PC; McConnell JD; Andriole GL; Geller J; Bracken BR; Tenover JS
    N Engl J Med; 1992 Oct; 327(17):1185-91. PubMed ID: 1383816
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endocrine treatment of benign prostatic hypertrophy: current concepts.
    Matzkin H; Braf Z
    Urology; 1991 Jan; 37(1):1-16. PubMed ID: 1702565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A prospective randomized trial comparing transurethral resection of the prostate and laser therapy in men with chronic urinary retention: The CLasP study.
    Gujral S; Abrams P; Donovan JL; Neal DE; Brookes ST; Chacko KN; Wright MJ; Timoney AG; Peters TJ
    J Urol; 2000 Jul; 164(1):59-64. PubMed ID: 10840425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.